Aditxt Acquires Ignite Proteomics for $36 Million

Aditxt Acquires Appili Therapeutics

October 10, 2024

Healthcare Services

Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.

Insightful Science Acquires Protein Metrics

December 21, 2021

Software

Insightful Science, a portfolio company of Insight Partners, has acquired Protein Metrics, a provider of protein characterization and proteomics analysis software. The deal adds proteomics capabilities to Insightful Science's R&D software portfolio (including GraphPad Prism, SnapGene, Geneious Prime and Dotmatics) to help biopharma and research customers accelerate protein analysis across research and production.

Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities

July 7, 2022

Healthcare Services

Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.

Illumina Acquires SomaLogic from Standard BioTools

January 30, 2026

Healthcare Services

Illumina, Inc. completed its acquisition of SomaLogic, adding data-driven proteomics technology to expand its multiomics portfolio. The deal was for $350 million in upfront cash at closing, plus up to $75 million in near-term performance-based milestones/royalties, with Illumina expecting to fund the transaction with cash on hand.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Johnson & Johnson to Acquire Proteologix, Inc.

May 16, 2024

Biotechnology

Johnson & Johnson entered into a definitive agreement to acquire privately held biotechnology company Proteologix for $850 million in cash, with potential additional milestone payments. The deal is expected to close mid-year 2024 subject to antitrust clearance and customary closing conditions, expanding J&J’s bispecific antibody pipeline for immune-mediated diseases including atopic dermatitis and asthma.